Results 191 to 200 of about 67,365 (299)

Glucagon-Like Peptide-1 Receptor Agonists Across the Heart Failure Spectrum: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Muller Ferreira V, Ayres Muller V.
europepmc   +1 more source

A new tool requires a new approach: glucagon-like peptide-1 receptor agonists and the scope of fertility care [PDF]

Wendy Vitek, Kassie J Bollig
openalex   +1 more source

Compartmentalisation in cAMP signalling: A phase separation perspective

British Journal of Pharmacology, EarlyView.
Cells rely on precise spatiotemporal control of signalling pathways to ensure functional specificity. The compartmentalisation of cyclic AMP (cAMP) and protein kinase A (PKA) signalling enables distinct cellular responses within a crowded cytoplasmic space.
Milda Folkmanaite, Manuela Zaccolo
wiley   +1 more source

Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart. [PDF]

Pharmaceutics
Neumann J, Kirchhefer U, Hofmann B, Gergs U.   +3 more
europepmc   +1 more source

The Isolated N-terminal Domain of the Glucagon-like Peptide-1 (GLP-1) Receptor Binds Exendin Peptides with Much Higher Affinity than GLP-1

, 2003
Rakel López de Maturana, Angela Willshaw, Antje Kuntzsch, Rainer Rudolph, Dan Donnelly   +4 more
openalex   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Accumulation and attenuation of cardiovascular benefit with glucagon-like peptide 1 receptor agonists. [PDF]

BMJ Med
Batty JA, Del Toro T, Hall M.
europepmc   +1 more source

Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis [PDF]

Yuqi Wang, LuDa Feng, Yajing Wang, Boyang Li, Ning Liang, Xuan Song, Jianguo Qin, Mianzhi Zhang, Yu Li   +8 more
openalex   +1 more source

Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions

British Journal of Pharmacology, EarlyView.
Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley   +1 more source

Effects of the glucagon-like peptide-1 receptor agonist PEG-Loxe on diabetic osteoporosis: A mechanistic study. [PDF]

Mol Metab
Zhang L, Hu J, Huang C, Gao X, Pang D, Duan L.   +5 more
europepmc   +1 more source